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participate.Effect of Valve Design on the Stent Internal Diameter of a Bioprosthetic Valve:
A Concept of True Internal Diameter and Its Implications for the Valve-in-Valve
Procedure115Vinayak N. Bapat, Rizwan Attia, Martyn Thomas
Transcatheter heart valves (THVs) are increasingly used to treat degenerated
surgical heart valves (SHVs). This novel treatment is promising and less invasive.
Choosing a correct THV size for a particular type of SHV is important to avoid
problems associated with oversizing and undersizing. Labeled size and the stent
internal diameter (ID) of an SHV are not accurate measurements of its true ID. We
measured the true ID of a variety of stented and 3 stentless valves and discuss its
implications on performing a valve-in-valve procedure. The authors also discuss
subtle differences when choosing a THV for aortic and mitral positions.Impact of New-Onset Persistent Left Bundle Branch Block on Late Clinical
Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation With
a Balloon-Expandable Valve128Marina Urena, John G. Webb, Asim Cheema, Vicenç Serra, Stefan Toggweiler, Marco Barbanti,
Anson Cheung, Jian Ye, Eric Dumont, Robert DeLarochellière, Daniel Doyle, Hatim A. Al Lawati,
Marc Peterson, Robert Chisholm, Albert Igual, Henrique Barbosa Ribeiro, Luis Nombela-Franco,
François Philippon, Bruno Garcia del Blanco, Josep Rodés-Cabau
The impact of new-onset persistent left bundle branch block (NOP-LBBB) after
transcatheter aortic valve implantation (TAVI) remains controversial. We evaluated
the impact of NOP-LBBB on late outcomes in 668 patients without a previous
pacemaker or left bundle branch block (LBBB) undergoing TAVI with a balloon-
expandable valve. NOP-LBBB occurred in 79 patients (11.8%). There were no
differences in global or cardiovascular mortality, sudden death, or rehospitalizations
for all causes or heart failure between the NOP-LBBB and no NOP-LBBB groups
at 1-year follow-up. NOP-LBBB was associated with an increased rate of perma-
nent pacemaker implantation, a lack of left ventricular ejection fraction improve-
ment, and a poorer New York Heart Association functional class at follow-up
(p < 0.02 for all).
See additional content in the online version of this issue.EDITORIAL COMMENTLeft Bundle Branch Block After Transcatheter Aortic Valve Implantation:
Still a Matter of Concern?137Laurent Roten, Bernhard Meier(continued on A-22)
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A-22Usefulness of Baseline Activated Clotting Time–Guided Heparin Administration
in Reducing Bleeding Events During Transfemoral Transcatheter Aortic
Valve Implantation140Chiara Bernelli, Alaide Chieffo, Matteo Montorfano, Francesco Maisano, Gennaro Giustino,
Gill Louise Buchanan, Jaclyn Chan, Charis Costopoulos, Azeem Latib, Filippo Figini,
Ermelinda De Meo, Francesco Giannini, Remo Daniel Covello, Chiara Gerli, Annalisa Franco,
Eustachio Agricola, Pietro Spagnolo, Micaela Cioni, Ottavio Alﬁeri, Paolo Guido Camici,
Antonio Colombo
Excessive intraprocedural anticoagulation with heparin may account for an
increased occurrence of bleeding during transcatheter aortic valve implantation.
However, no real standards to guide heparin dosing have been established in this
ﬁeld. Among 362 patients undergoing transfemoral transcatheter aortic valve
implantation, heparin was administered according to baseline activated clotting time
(ACT) (ACT-guided, n ¼ 174) or patient’s body weight (non–ACT-guided, n ¼
188). The ACT-guided group had a signiﬁcantly lower occurrence of major (7.5%
vs. 33.5%, p < 0.001), life-threatening (12.1% vs. 20.2%, p ¼ 0.04), and any
bleeding (25.9% vs. 64.9%, p < 0.001). This data suggest that the ACT-guided
strategy might be a useful tool in reducing bleeding in this high-risk frail study
group.EDITORIAL COMMENTBleeding Avoidance in Transcatheter Aortic Valve Replacement:
A Call to ACTion?152Matthew I. Tomey, Roxana MehranTransapical Mitral Implantation of the Tiara Bioprosthesis:
Pre-Clinical Results154Shmuel Banai, Stefan Verheye, Anson Cheung, Marc Schwartz, Alexei Marko, Randy Lane,
E. Marc Jolicoeur, Patrick Garceau, Simon Biner, Jean-Francois Tanguay, Elazer R. Edelman,
Christopher J. White
The authors describe the pre-clinical evaluation of the Tiara (Neovasc Inc,
Vancouver, British Columbia, Canada), a transcatheter self-expanding mitral bio-
prosthesis, in short-term and long-term animal models, and in a human cadaveric
model. Excellent function and alignment of the valves were demonstrated, with no
left ventricular outﬂow tract or coronary obstruction, and/or transvalvular gradients.
In the long-term model, a mild degree of prosthetic valve regurgitation was seen in
2 of the 7 sheep. In human cadaver hearts, proper anatomic alignment and
anchoring of the Tiara were demonstrated. Pre-clinical evaluation shows that
transapical mitral implantation of the Tiara valve is feasible and safe, and results in
a stable and well-functioning mitral bioprosthesis.(continued on A-23)
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Clinical ResearchCarotid Angioplasty With Stenting Versus Endarterectomy:
10-Year Randomized Trial in a Community Hospital163William H. Brooks, Michael R. Jones, Paula Gisler, Rick R. McClure, Timothy C. Coleman,
Linda Breathitt, Cheryl Spear
This randomized trial demonstrated a long-term (10-year) clinical similarity
between carotid stenting without cerebral embolic protection and carotid endar-
terectomy in a cohort of patients with mixed surgical risk. Nonfatal strokes were
observed only in the stented group but were unrelated to the treated artery. A single
death from stroke ipsilateral to the treated artery occurred after 7 years in the stented
group. Myocardial infarction was more common in patients presenting with
symptomatic versus asymptomatic carotid disease (27.5% vs. 11.0%; hazard ratio
[HR]: 2.32, 95% conﬁdence interval [CI]: 1.298 to 4.146, p ¼ 0.005) and in all
treated with carotid endarterectomy versus carotid angioplasty and stenting (HR:
2.27, 95% CI: 1.350 to 3.816, p ¼ 0.002) Asymptomatic restenosis occurred only in
the stented cohort, with an annual risk of 0.3%.EDITORIAL COMMENTCarotidEndarterectomyVersusCarotidArteryStenting:CaseClosed.NowWhat!? 169Robert D. SaﬁanComparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting:
An NCDR Analysis (National Cardiovascular Data Registry)171Jay Giri, Kevin F. Kennedy, Ido Weinberg, Beau M. Hawkins, Marcella Calfon Press,
Douglas Drachman, Daniel J. McCormick, Herbert D. Aronow, Christopher J. White,
Kenneth Rosenﬁeld, Robert W. Yeh
A variety of stents and embolic protection devices are used for carotid artery
stenting. Little is known about current usage patterns and differences in outcomes
with these devices. We analyzed 12,135 consecutive carotid stent procedures in the
NCDR (National Cardiovascular Data Registry) CARE (Carotid Artery Revas-
cularization and Endarterectomy) registry comparing crude and multivariable-
adjusted rates of in-hospital combined death/stroke among patients treated with
Acculink/Accunet (Abbott Laboratories, Abbott Park, Illinois), Xact/Emboshield
(Abbott), and Precise/Angioguard (Cordis Corporation, Bridgewater, New Jersey)
stent/embolic protection device combinations. The 3 systems were used in the
majority of U.S. cases and were associated with similarly low rates of in-hospital
death and stroke.EDITORIAL COMMENTContemporary Carotid Stenting: Comparative Effectiveness Research From
the NCDR (National Cardiovascular Data Registry)178Paul T. Vaitkus(continued on A-24)
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A-24Carotid Artery Stenting for Recurrent Carotid Artery Restenosis After Previous
Ipsilateral Carotid Artery Endarterectomy or Stenting: A Report From the
National Cardiovascular Data Registry180Brian G. Hynes, Kevin F. Kennedy, Nicholas J. Ruggiero, II, Thomas J. Kiernan,
Ronan J. Margey, Kenneth Rosenﬁeld, Joseph M. Garasic
Using CARE (Carotid Artery Revascularization and Endarterectomy) registry data,
we sought to evaluate and compare outcomes of patients undergoing carotid artery
stenting (CAS) for ipsilateral restenosis, either after previous CAS or carotid artery
endarterectomy (CEA) (CAS-R group) with those of patients who had CAS
performed for de novo carotid atherosclerotic stenosis (CAS-DN group).
Propensity score matching yielded 1,756 patients in each CAS cohort. The primary
endpoint composite of in-hospital death or stroke or myocardial infarction occurred
less often in CAS-R compared with CAS-DN patients (1.9% vs. 3.2%, p ¼ 0.019).
Patients who underwent CAS for restenosis after previous ipsilateral revasculari-
zation had lower periprocedural adverse event rates.
JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.See additional content in the online version of this issue.Anatomical Eligibility of the Renal Vasculature for Catheter-Based
Renal Denervation in Hypertensive Patients187Stefano F. Rimoldi, Niklaus Scheidegger, Urs Scherrer, Stefan Farese, Emrush Rexhaj,
Aris Moschovitis, Stephan Windecker, Bernhard Meier, Yves Allemann
To improve the number of controlled hypertensive patients, novel invasive strategies
have been developed. Catheter-based renal artery denervation (RDN) is the most
promising one. However, there are few data on the renal vascular anatomical
eligibility in this patient population. In this large study, we showed that 53% of the
resistant and 52% of the nonresistant hypertensive patients were anatomically
eligible. Anatomical eligibility criteria included in the current guidelines are a major
limiting factor for RDN. Development of new devices and/or techniques may
signiﬁcantly increase the number of patients that may take advantage of RDN.EDITORIAL COMMENTAnatomical Exclusion for Renal Denervation: Are We Putting the
Cart Before the Horse?193Mehdi H. Shishehbor, Matthew C. Bunte(continued on A-25)
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A-25CORONARY
Clinical ResearchPredicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation): Coronary Anatomy Versus
Ischemia195G. B. John Mancini, Pamela M. Hartigan, Leslee J. Shaw, Daniel S. Berman, Sean W. Hayes,
Eric R. Bates, David J. Maron, Koon Teo, Steven P. Sedlis, Bernard R. Chaitman,
William S. Weintraub, John A. Spertus, William J. Kostuk, Marcin Dada, David C. Booth,
William E. Boden
Anatomic burden and ischemic burden of coronary artery disease determine patient
prognosis and inﬂuence myocardial revascularization decisions. When both
measures are available, their relative utility for prognostication and management
choice is controversial. A total of 621 patients enrolled in the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial with
baseline quantitative nuclear single-photon emission computed tomography and
quantitative coronary angiography were studied. In this cohort of patients treated
with optimal medical therapy, anatomic burden was a consistent predictor of death,
myocardial infarction, or non–ST-segment acute coronary syndromes, whereas
ischemic burden was not. Neither parameter, even in combination, identiﬁed
a patient proﬁle beneﬁting preferentially from an invasive therapeutic strategy.EDITORIAL COMMENTIs it Form or Function?: The “COURAGE” to Ask 202Spencer B. King, IIIA Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon Versus
Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis:
Results From the PEPCAD China ISR Trial204Bo Xu, Runlin Gao, Jian’an Wang, Yuejin Yang, Shaoliang Chen, Bin Liu, Fang Chen,
Zhanquan Li, Yaling Han, Guosheng Fu, Yelin Zhao, Junbo Ge, for the PEPCAD China
ISR Trial Investigators
PEPCAD China ISR (A Prospective, Multicenter, Randomized Trial of Paclitaxel-
Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting
Stent In-Stent Restenosis) compared the paclitaxel-coated balloon (PCB) and the
paclitaxel-eluting stent for treatment of drug-eluting stent in-stent restenosis in the
Chinese population. The 9-month primary endpoint was met with an in-segment
late lumen loss of 0.46  0.51 mm in the PCB group versus 0.55  0.61 mm in the
paclitaxel-eluting stent group (p for noninferiority ¼ 0.0005). The 12-month
clinical event rates were not signiﬁcantly different between groups. On the basis of
these as well as previous randomized trial data, PCB angioplasty offers an effective
treatment for drug-eluting stent in-stent restenosis without the necessity of
implanting additional metal layers for drug release.
See additional content in the online version of this issue.(continued on A-26)
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A-26Immediate Results and Long-Term Clinical Outcome of Patients With Unprotected
Distal Left Main Restenosis: The CORPAL Registry (Córdoba and Las Palmas)212Soledad Ojeda, Manuel Pan, Pedro Martín, Francisco Mazuelos, Javier Suárez de Lezo,
Miguel Romero, José Segura, Djordje Pavlovic, Alfonso Medina, Jose Suárez de Lezo
From 1,102 patients with unprotected distal left main coronary artery disease
treated with drug-eluting stents, we analyzed the immediate and long-term clinical
outcomes of 75 patients with restenosis treated by a simple approach (balloon/in-
stent implantation) or a complex strategy (additional stent/double-stenting tech-
nique). The incidence of major adverse cardiac events (MACE) at follow-up was
lower in patients treated with a simple approach, regardless of the restenosis extent
(mild restenosis: 93% vs. 67%, p < 0.05; severe: 70% vs. 23%, p < 0.05). On Cox
analysis, diabetes was the only predictor of MACE (hazard ratio [HR]: 4.94; 95%
conﬁdence interval [CI]: 1.03 to 23.70; p < 0.05), whereas a simple strategy was
associated with a lower risk (HR: 0.25; 95% CI: 0.08 to 0.79; p ¼ 0.02).IMAGES IN
INTERVENTIONCoreValve Frame Distortion: The Importance of Meticulous Valve Loading 222Andrew Wiper, Anoop Chauhan, Ranjit More, David RobertsExtrinsic Compression of the Left Anterior Descending Coronary Artery
During Percutaneous Pulmonary Valve Implantation224Victor A. Jiménez, Andrés Íñiguez, José A. Baz, Jorge Sepúlveda, José L. Zunzunegui
This article has accompanying videos that can be viewed in the online
version of this issue.Acute Myocardial Infarction After Left-Heart Catheterization
in a Patient With Severe Calciﬁed Bicuspid Aortic Stenosise5Christian Dauvergne, Mario Araya, Julia Valenzuela, Manuel Meneses, Rafael Selman,
Gabriel MaluendaMultivessel Honeycomb-Like Structure Finding in
Optical Coherence Tomographye7Mio Musashi, Norio Tada, Naoki Uemura, Osamu Kawashima, Tatsushi Ootomo, Naoto Inoue,
Hideki Abe, Taiichiro MeguroSpontaneous Right Coronary Artery Dissection:
A Case of Spontaneous Resolutione9Moses Mathur, Nazmul Huda, Howard Cohen, Ted ParrisPrevention of Cerebral Embolization by Placing
a Neuroprotection Filter Before Recoarctation Stent Dilatione11Dobrin Iotkov Vassilev, Gianluca Rigatelli, Ana Kaneva-Nencheva, Elisaveta Levunlieva,
Alexander Alexandrov(continued on A-27)
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A-27Very Late Ventricular Displacement of Transcatheter
Aortic Valve Resulting in Severe Paravalvular Regurgitatione13Roshan Prakash, Gareth Crouch, Majo X. Joseph, Jayme Bennetts, Joseph B. Selvanayagam,
Ajay Sinhal
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